首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1746643

日本神經生物標記市場報告（按類型、應用、最終用途和地區）2025-2033

Japan Neurological Biomarkers Market Report by Type, Application, End Use, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 115 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本神經生物標記市場規模達5.914億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到9.553億美元，2025-2033年期間的複合年成長率（CAGR）為5.50%。有效治療方案的採用率不斷上升，以及對快速藥物開發的需求不斷成長，是推動市場成長的主要動力。

神經生物標記存在於血液或腦脊髓液 (CSF) 中，有助於識別腦部疾病並追蹤疾病進展。這些生物標記主要來自基因突變、代謝物水平、腦部影像以及蛋白質表現改變或翻譯後修飾。神經生物標記物能夠識別實驗藥物的生物反應，並有助於探索新的治療介入靶點，因此在整個藥物開發過程中的臨床應用中發揮重要作用。目前，科學家透過分析這些生物標記的濃度，可以進行非侵入性檢測、早期診斷和個人化治療。

日本神經生物標記市場趨勢：

日本神經系統生物標記市場正經歷顯著成長，這得益於神經系統疾病的日益流行，包括中風、運動神經元疾病 (MND)、阿茲海默症 (AD)、帕金森氏症 (PD) 和亨廷頓氏症 (HD)。神經系統疾病的激增催生了對加速藥物開發的迫切需求，從而推動了市場的成長。此外，生物標記在衡量新型藥物和治療方法的有效性方面發揮關鍵作用，對這一發展勢頭做出了重要貢獻。此外，微創手術和個人化醫療實踐的日益普及，也成為該地區市場擴張的另一個重要催化劑。此外，由於各種神經系統疾病通常具有共同的特徵，因此對多種生物標記的需求日益成長，以區分特定疾病及其亞型，這進一步刺激了市場需求。此外，質譜和成像技術的進步促進了對腦內多種生化標記和結構變化的快速評估，從而提高了診斷能力。再加上數位生物標記的引入和臨床試驗數量的持續增加，預計將在未來幾年進一步推動日本神經生物標記市場的成長。

日本神經生物標記市場細分：

類型洞察：

基因組生物標記
蛋白質體生物標記
代謝組學生物標記
成像生物標記
其他

應用程式洞察：

阿茲海默症
帕金森氏症
多發性硬化症
自閉症譜系障礙
其他

最終用途洞察：

醫院實驗室
臨床診斷中心
研究機構
其他

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本神經生物標記市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本神經生物標記市場有何影響？
日本神經生物標記市場依類型分為哪些類型？
日本神經生物標記市場根據應用如何分類？
根據最終用途，日本神經生物標記市場是如何分類的？
日本神經生物標記市場的價值鏈分為哪些階段？
日本神經生物標記的主要促進因素和挑戰是什麼？
日本神經生物標記市場的結構是怎麼樣的？主要參與者是誰？
日本神經生物標記市場的競爭程度如何？

本報告回答的關鍵問題：

日本神經生物標記市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本神經生物標記市場有何影響？
日本神經生物標記市場依類型分為哪些類型？
日本神經生物標記市場根據應用如何分類？
根據最終用途，日本神經生物標記市場是如何分類的？
日本神經生物標記市場的價值鏈分為哪些階段？
日本神經生物標記的主要促進因素和挑戰是什麼？
日本神經生物標記市場的結構是怎麼樣的？主要參與者是誰？
日本神經生物標記市場的競爭程度如何？

Japan neurological biomarkers market size reached USD 591.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 955.3 Million by 2033, exhibiting a growth rate (CAGR) of 5.50% during 2025-2033. The inflating adoption of effective treatment plans and the escalating demand for faster drug development are primarily driving the market growth.

Neurological biomarkers, found in either the blood or cerebral spinal fluid (CSF), serve to facilitate the identification of brain disorders and track the advancement of diseases. These biomarkers primarily originate from genetic mutations, levels of metabolites, brain imaging, and alterations in the expression of proteins or modifications after translation. With their ability to identify biological reactions to experimental medications and assist in the exploration of novel targets for therapeutic intervention, neurological biomarkers play a significant role in clinical applications throughout the drug development process. Currently, scientists analyze the concentrations of these biomarkers to enable non-invasive testing, early diagnosis, and the customization of treatments.

Japan Neurological Biomarkers Market Trends:

The Japan neurological biomarkers market is witnessing a notable upsurge owing to the escalating prevalence of neurological disorders, including conditions like stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). This surge in neurological disorders has generated a pressing demand for accelerated drug development, thereby driving the market growth. Besides this, biomarkers play a pivotal role in measuring the effectiveness of novel medications and therapeutic approaches, contributing significantly to this momentum. Additionally, the growing acceptance of minimally invasive procedures and personalized medicine practices is serving as another crucial catalyst for market expansion in the region. Furthermore, as various neurological disorders often exhibit shared characteristics, there is an increasing requirement for multiple biomarkers to differentiate between specific diseases and their subtypes, further fueling market demand. Apart from this, advancements in mass spectrometry and imaging techniques have facilitated the rapid evaluation of numerous biochemical markers and structural changes within the brain, enabling enhanced diagnostic capabilities. This, coupled with the introduction of digital biomarkers and the continual rise in the number of clinical trials, is expected to further propel the growth of the Japan neurological biomarkers market in the forthcoming years.

Japan Neurological Biomarkers Market Segmentation:

Type Insights:

Genomic Biomarkers
Proteomic Biomarkers
Metabolomic Biomarkers
Imaging Biomarkers
Others

Application Insights:

Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others

End Use Insights:

Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan neurological biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan neurological biomarkers market?
What is the breakup of the Japan neurological biomarkers market on the basis of type?
What is the breakup of the Japan neurological biomarkers market on the basis of application?
What is the breakup of the Japan neurological biomarkers market on the basis of end use?
What are the various stages in the value chain of the Japan neurological biomarkers market?
What are the key driving factors and challenges in the Japan neurological biomarkers?
What is the structure of the Japan neurological biomarkers market and who are the key players?
What is the degree of competition in the Japan neurological biomarkers market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Neurological Biomarkers Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Neurological Biomarkers Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Neurological Biomarkers Market - Breakup by Type

6.1 Genomic Biomarkers
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Proteomic Biomarkers
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Metabolomic Biomarkers
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Imaging Biomarkers
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Others
- 6.5.1 Historical and Current Market Trends (2019-2024)
- 6.5.2 Market Forecast (2025-2033)

7 Japan Neurological Biomarkers Market - Breakup by Application

7.1 Alzheimer's Disease
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Parkinson's Disease
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Multiple Sclerosis
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Autism Spectrum Disorders
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Others
- 7.5.1 Historical and Current Market Trends (2019-2024)
- 7.5.2 Market Forecast (2025-2033)

8 Japan Neurological Biomarkers Market - Breakup by End Use

8.1 Hospital Laboratories
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Clinical Diagnostic Centers
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Research Organizations
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Others
- 8.4.1 Historical and Current Market Trends (2019-2024)
- 8.4.2 Market Forecast (2025-2033)

9 Japan Neurological Biomarkers Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Services Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Services Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Services Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Services Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Services Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Neurological Biomarkers Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis